CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
bone marrow transplantbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03240731
NCT03240731Phase 2Completed
CompareCT.gov

Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease

Centre Hospitalier Intercommunal Creteil·interventional·Posted Aug 7, 2017·Updated Sep 2, 2025

In Brief

A Phase 2 clinical trial evaluating bone marrow transplant for Sickle Cell Disease. Completed, enrolled 25 participants across 7 sites.

Detailed Summary

multicentric interventional biomedical research phase II, prospective, non-randomized evaluating a haploidentical marrow transplants after reduced-intensity conditioning and prevention of GvHD based on cyclophosphamide administration post transplantation in patients with severe sickle cell disease.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSickle Cell Disease
CountriesFrance
CollaboratorsKeocyt, Association Clinique Thérapeutique Infantile du val de Marne

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 7, 2017
Enrollment StartAug 10, 2017
Primary CompletionApr 8, 2024
TodayJul 2, 2026
Enrollment to primary: 6.7 yearsPosted 8.9 years ago

Interventions

bone marrow transplantbiological

haploidentical bone marrow transplant